sorry ma420, I believe you're not reading my post correctly?
paediatric AML is difficult due to rarity and demographic. That's not what management is pursuing
EMD AML, which is our current strategy for 505b2 approval, has a lot of interest from clinicians as it is currently excluded due to difficulty in treatment.
This is what I was trying to relay in my post to Titans.
General Comments / Chat, page-4900
-
- There are more pages in this discussion • 6,216 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |